# Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

> **NCT01661790** · PHASE3 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 72 (actual)

## Conditions studied

- Malignant Pleural Effusion

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01661790
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2015-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661790, "Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT01661790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*